



## Vaxart to Present at ASM Microbe 2018

May 31, 2018

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 31, 2018-- Vaxart, Inc. (NASDAQ:VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.D., lead scientist of Vaxart, will present data on the Phase 1 norovirus vaccine trial in a poster presentation at the American Society of Microbiology 2018, taking place from June 7-11, 2018 in Atlanta, Georgia.

Details of the presentation are as follows:

**Presentation Title:** *Cross Reactivity Following Oral Norovirus Vaccination in Humans and Ferrets*

**Date & Time:** Sunday, June 10, 2018 from 12:45 PM – 2:45 PM EST

**Authors:** Roberto Mateo, et al.

**Session:** Vaccines and Immunization Science; Viruses and Pertusis

"We continue to be encouraged by the cross reactivity data from our norovirus vaccine program and look forward to sharing it with thought leaders in infectious disease and microbiology this month at ASM Microbiome," said Sean Tucker, Ph.D., founder and chief scientific officer of Vaxart.

All recent publications are available on the Vaxart website under Newsroom at [www.vaxart.com](http://www.vaxart.com).

### About Vaxart

Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform. Vaxart's vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Vaxart's vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart believes that tablet vaccines are easier to distribute and administer than injectable vaccines, and have the potential to significantly increase vaccination rates. Vaxart's development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). Vaxart is also developing several small-molecule antiviral drug candidates, including teslexivir (BTA074), an antiviral treatment for condyloma caused by HPV types 6 and 11. For more information, please visit [www.vaxart.com](http://www.vaxart.com).

### Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, prospects, plans and objectives, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as "believe," "could," "potential" and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to the Vaxart's ability to develop and commercialize its product candidates. Vaxart may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, that Vaxart's product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart's product candidates may not achieve broad market acceptance; and the risks described from time to time in the reports Vaxart files with the Securities and Exchange Commission, or SEC, including its Form 10-Q for the three months ended March 31, 2018. Copies of reports filed with the SEC are posted on Vaxart's website and are available from Vaxart without charge. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180531006477/en/>

Source: Vaxart, Inc.

Stern Investor Relations  
Carl Mauch, 212-362-1200  
[vaxart@sternir.com](mailto:vaxart@sternir.com)